NCIt definition : A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with
potential immunostimulating and antineoplastic activities. Blinatumomab possesses
two antigen-recognition sites, one for the CD3 complex, a group of T cell surface
glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated
antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal
antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and
helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated
cell death of CD19-expressing B-lymphocytes.;
UNII : 4FR53SIF3A;
CAS number : 853426-35-4;
Drug name : Blincyto;
Molecule name : MEDI-538; MT-103; AMG 103; MEDI 538; AMG-103; MT 103;